⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301809 | 0.83 | — | — | |
| SCHEMBL11148312 | 0.80 | — | — | |
| SCHEMBL29307219 | 0.80 | — | — | |
| SCHEMBL18759852 | 0.80 | — | — | |
| SCHEMBL3791692 | 0.77 | KDM4E (0.30) | — | |
| SCHEMBL3011767 | 0.77 | — | — | |
| SCHEMBL19075449 | 0.75 | — | — | |
| Phosphine SCHEMBL27708157 | 0.75 | — | — | |
| SCHEMBL2688498 | 0.75 | — | — | |
| SCHEMBL157070 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115572252-B | Isoindolinone inhibitors of MDM2-P53 interaction with anticancer activity | 阿斯泰克斯治疗有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-116964028-A | Process for producing carbonyl halide | 国立大学法人神户大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-116940548-A | Process for producing carbonyl halide | 国立大学法人神户大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-115572252-A | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-108290871-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-113015719-A | Method for producing isocyanate compound | 国立大学法人神户大学 | 2021-06-22 | — | — | CN | disclosed |
| US-20200247789-A2 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUCTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |